Indian Journal of Cancer Home 

POSITION PAPER
[View FULLTEXT] [Download PDF]
Year : 2012  |  Volume : 49  |  Issue : 1  |  Page : 46--56

Optimizing second-line therapy for chronic myeloid leukemia

T Raja 
 Department of Medical Oncology, Apollo Speciality Hospitals, Chennai, India

Correspondence Address:
T Raja
Department of Medical Oncology, Apollo Speciality Hospitals, Chennai
India

Treatment of chronic myeloid leukemia has evolved from symptom control to long-term disease-free survival with cure potentially round the corner. This required faster, deeper, and longer response. Optimizing treatment decisions therefore requires clear understanding of and strict implementation of guidelines for shift from imatinib. In patients who are resistant to or intolerant of imatinib, second-line TKIs have to be selected carefully. Currently available data show comparable efficacy between nilotinib and dasatinib. With a better safety profile (especially with respect to grade 3 or 4 hematologic toxicity and clinically relevant non-hematologic toxicities), nilotinib becomes the preferred choice in most instances.


How to cite this article:
Raja T. Optimizing second-line therapy for chronic myeloid leukemia.Indian J Cancer 2012;49:46-56


How to cite this URL:
Raja T. Optimizing second-line therapy for chronic myeloid leukemia. Indian J Cancer [serial online] 2012 [cited 2020 Jul 13 ];49:46-56
Available from: http://www.indianjcancer.com/article.asp?issn=0019-509X;year=2012;volume=49;issue=1;spage=46;epage=56;aulast=Raja;type=0